Format

Send to

Choose Destination
JAMA Intern Med. 2017 Nov 1;177(11):1569-1575. doi: 10.1001/jamainternmed.2017.3601.

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.

Author information

1
Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland.
2
Department of Preventive Medicine and Public Health, Oregon Health and Science University, Portland.
3
Center for Health Care Ethics, Oregon Health and Science University, Portland.
4
Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
5
Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York.

Erratum in

Abstract

Importance:

A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication.

Objective:

To provide a contemporary estimate of R&D spending to develop cancer drugs.

Design, Setting, and Participants:

Analysis of US Securities and Exchange Commission filings for drug companies with no drugs on the US market that received approval by the US Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015. Cumulative R&D spending was estimated from initiation of drug development activity to date of approval. Earnings were also identified from the time of approval to the present. The study was conducted from December 10, 2016, to March 2, 2017.

Main Outcomes and Measures:

Median R&D spending on cancer drug development.

Results:

Ten companies and drugs were included in this analysis. The 10 companies had a median time to develop a drug of 7.3 years (range, 5.8-15.2 years). Five drugs (50%) received accelerated approval from the US Food and Drug Administration, and 5 (50%) received regular approval. The median cost of drug development was $648.0 million (range, $157.3 million to $1950.8 million). The median cost was $757.4 million (range, $203.6 million to $2601.7 million) for a 7% per annum cost of capital (or opportunity costs) and $793.6 million (range, $219.1 million to $2827.1 million) for a 9% opportunity costs. With a median of 4.0 years (range, 0.8-8.8 years) since approval, the total revenue from sales of these 10 drugs since approval was $67.0 billion compared with total R&D spending of $7.2 billion ($9.1 billion, including 7% opportunity costs).

Conclusions and Relevance:

The cost to develop a cancer drug is $648.0 million, a figure significantly lower than prior estimates. The revenue since approval is substantial (median, $1658.4 million; range, $204.1 million to $22 275.0 million). This analysis provides a transparent estimate of R&D spending on cancer drugs and has implications for the current debate on drug pricing.

Comment in

PMID:
28892524
PMCID:
PMC5710275
DOI:
10.1001/jamainternmed.2017.3601
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center